Posts

Novartis to buy Regulus Therapeutics for up to $1.7B

on

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

on

AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap

on

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

on

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

on

AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data

on

Novartis off to "strong" start, prompting guidance raise for 2025

on

AstraZeneca's China woes recede as focus shifts to upcoming readouts

on

Lilly taps Creyon's AI-enabled oligo tech in heavily backloaded $1B deal

on

FDA decision on Stealth's Barth syndrome drug delayed, again

on

Abeona's $3.1M gene therapy wins FDA nod for rare skin disease

on

Merck & Co. breaks ground on $1B future US home of Keytruda

on

AbbVie's Rinvoq cleared for giant cell arteritis in US

on

Pfizer's Bourla is 'cautiously optimistic' on tariffs, says M&A is on the table

on

Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring

on

Regeneron crumples under the weight of missed Eylea expectations

on

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

on

As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense

on

FDA approves Abeonas skin disease cell therapy

on

Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027

on

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

on

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

on

HHS lifts stop work order on Vaxart's COVID-19 trial, continues funding for the 10,000-participant study

on

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

on

France pauses chikungunya vaccinations in the elderly after patient death

on

AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer

on

Pfizer's Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

on

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

on

'Deviated from the core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult

on

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

on

Keytruda around head and neck cancer surgery cuts chance of disease coming back

on

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

on

Roche's WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25

on

Akeso's PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer

on

Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch

on